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Surgical resection of solid primary malignancies is a mainstay of therapy for cancer patients.
Despite being the most effective treatment for these tumors, cancer surgery has been
associated with impaired metastatic clearance due to immunosuppression. In preclinical
surgery models and human cancer patients, we and others have demonstrated a profound
suppression of both natural killer (NK) andT cell function in the postoperative period and this
plays a major role in the enhanced development of metastases following surgery. Oncolytic
viruses (OV) were originally designed to selectively infect and replicate in tumors, with the
primary objective of directly lysing cancer cells. It is becoming increasingly clear, however,
that OV infection results in a profound inflammatory reaction within the tumor, initiating
innate and adaptive immune responses against it that is critical for its therapeutic bene-
fit. This anti-tumor immunity appears to be mediated predominantly by NK and cytotoxic
T cells. In preclinical models, we found that preoperative OV prevents postoperative NK
cell dysfunction and attenuates tumor dissemination. Due to theoretical safety concerns of
administering live virus prior to surgery in cancer patients, we characterized safe, attenu-
ated versions of OV, and viral vaccines that could stimulate NK cells and reduce metastases
when administered in the perioperative period. In cancer patients, we observed that in vivo
infusion with oncolytic vaccinia virus and ex vivo stimulation with viral vaccines promote
NK cell activation.These preclinical studies provide a novel and clinically relevant setting for
OV therapy. Our challenge is to identify safe and promising OV therapies that will activate
NK andT cells in the perioperative period preventing the establishment of micrometastatic
disease in cancer patients.
Keywords: metastasis, postoperative period, oncolytic viruses, viral vaccines, cancer, perioperative immunostimu-
lation, natural killer cells, surgical stress
SURGICAL STRESS PROMOTES THE FORMATION
OF METASTASES
Surgical resection is the mainstay of therapy for most solid malig-
nancies but, even with complete resection, many patients harbor
microscopic residual disease and ultimately die of a recurrence
(1). Our group (2, 3) and others have clearly demonstrated, using
different animal and tumor models, that surgery promotes the for-
mation of metastatic disease (4–11) and the number of metastatic
deposits is directly proportional to the magnitude of surgical stress
(6, 12). In clinical studies, a complicated postoperative course
correlates with inferior cancer survival and increased incidence
of metastases (13, 14). A number of perioperative changes have
been proposed to explain the promotion of metastases forma-
tion following surgery including (1) dissemination of tumor cells
during the surgical procedure (15–20), (2) local and systemic
release of growth factors, such as vascular endothelial growth fac-
tor (VEGF) (21, 22), and (3) cellular immune suppression. The
cellular immune suppression following major surgery appears to
peak at 3 days (23) following surgery but may persist for weeks
(7, 23–25). It is hypothesized to be mediated by secretion of stress
hormones, such as glucocorticoids (26, 27), catecholamines (27–
29), and prostaglandins (26). It is characterized by both plasma
cytokine changes [a decrease in IL-2 (30), IL-12 (31) and an
increase IL-6 (27,30,32,33), IL-10 (34)] and a decrease in the num-
ber and function of circulating lymphocytes [cytotoxic T cells (35),
dendritic cells (DC) (36) and natural killer (NK) cells (2, 3, 37)].
The postoperative stress response represents a diverse set of
physiological changes that have evolved to ensure that the host
can heal following major tissue trauma. These changes, however,
involve pathways and mediators that can be exploited by cancer
cells to facilitate metastatic spread. While a number of correl-
ative studies have demonstrated an association between some of
these changes and the enhanced formation of metastases following
surgery, few mechanistic studies have been undertaken to under-
stand it. This review will focus on the importance of both innate
and adaptive postoperative cellular immune suppression, specifi-
cally NK and cytotoxic T cell postoperative dysfunction and make
the case for the use of preoperative oncolytic viruses (OV) and viral
vaccines to prevent the promotion of cancer metastases following
surgery.
SURGICAL STRESS INHIBITS NK CELL FUNCTION AND
ANTIGEN-SPECIFIC CD8+ T CELL FUNCTION
Both the innate and adaptive immune system play a significant
role in anti-tumor immunity. As integral members of the innate
immune system, NK cells are involved in the direct killing of cells
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displaying abnormalities linked to infection, malignancy, or trans-
plantation (38, 39). Immunosurveillance of the host by NK cells
for malignant cells results in direct cytotoxicity and the production
of cytokines to enhance the immune response (39).
Natural killer cell dysfunction following surgery, as measured
in a standard [51-Cr]-release assay, has been documented in both
human patients (3, 25, 40–42) and animal models (3, 5, 7, 40, 41,
43). Postoperative NK cell suppression correlates with increased
metastases in animal models of spontaneous (3, 9) and implanted
(3, 10, 11) metastases, while in human studies low NK activity
during the perioperative period is associated with a higher rate
of cancer recurrence and mortality in a number of different can-
cer types (44–46). Despite the large number of studies that have
documented postoperative NK cell dysfunction, very few studies
have thoroughly characterized and directly explored the mecha-
nism of this suppression (9, 11, 47). Our laboratory has clearly
defined a role for NK cells in the development of postopera-
tive metastases (2). Using several reproducible mouse models of
surgical stress, including B16 melanoma, CT26 colon cancer and
4T1 breast cancer, our laboratory has demonstrated a consistent
and significant (two- to fourfold) increase in the formation of
experimental and spontaneous pulmonary metastases following
surgery. In these experimental models, surgery markedly reduced
NK cell total numbers in the spleen and affected NK cell migra-
tion. Further, ex vivo and in vivo tumor cell killing by NK cells
were significantly reduced in surgically stressed mice. To estab-
lish that NK cells play the crucial mediating role in clearing tumor
metastases following surgery, we transferred surgically stressed NK
cells into NK-deficient mice (IL-2γR-knock out) and observed
enhanced lung metastases in tumor-bearing mice compared to
mice who received untreated NK cells (3). Transfer of NK cells
labeled with the NK specific marker DX5 from surgically stressed
and no surgery control donors into naive recipient mice represents
the first in vivo evidence that links surgery to the spread of cancers
via NK cells (3). In human studies, we have also confirmed that
postoperative cancer surgery patients had markedly reduced NK
cell cytotoxicity (3).
The adaptive immune system and more specifically CD8+ T
cells responses have received the majority of the attention from
the cancer immunity field. Of recent interest in our lab is the
impact of surgical stress on the development and maintenance
of an acquired T cell-mediated anti-tumor immune response. A
global reduction in T cell numbers and function post-surgery has
been documented in preclinical studies and cancer patients (35).
However, the effects of tumor-associated antigen (TAA)-specific
T cells have not been evaluated and represent a current focus of
research interest in our lab.
POSTOPERATIVE CELLULAR IMMUNE SUPPRESSION
IS REVERSIBLE
Fortunately postoperative immune suppression is reversible, so
while the postoperative period provides a window of opportunity
for cancer cells to metastasize and grow, it also provides a window
of opportunity to intervene, by supporting or further stimulating
the immune system, and, in doing so, attenuate the development of
cancer recurrences (48, 49). Based on promising preclinical results
(8, 50, 51), clinical trials of preoperative non-specific immune
stimulation with low-dose recombinant IFNα (52) or IL-2 (53–
58) have demonstrated less NK and T cell suppression following
surgery. In two randomized studies of patients undergoing resec-
tion of colorectal cancer (CRC) primary tumors (58) and hepatic
metastases (57), preoperative low-dose subcutaneous (s.c.) IL-2
was associated with an improved prognosis. In the first study, 86
CRC patients with stage II or III disease were randomized to receive
low-dose IL-2 twice a day for 3 consecutive days prior to surgery or
no preoperative treatment. At a median follow-up of 54 months,
there were significantly few recurrences in the IL-2 group (21.4
vs. 43.1%, p= 0.03) and a trend toward improved overall survival
(OS). In the second study, 50 CRC patients with Stage IV disease,
undergoing curative or palliative surgery, were randomized to the
same two treatment arms. The median progression-free survival
(PFS) and OS were significantly longer in the preoperative IL-2
group. While these studies were not designed to evaluate cancer
outcomes, a Phase II trial in 120 patients undergoing resection
for renal-cell carcinoma has demonstrated a significant improve-
ment in 5-year PFS with preoperative IL-2 (74 vs. 62%, p= 0.02)
(54). Moreover, in all of these studies, preoperative IL-2 was safe
and well tolerated with adverse events limited to pyrexia (Grade I–
III). A few other non-conventional immunomodulators have been
evaluated for their ability to boost cellular immunity in the periop-
erative period including cimetidine (59, 60), mistletoe extract (61,
62), and granulocyte colony-stimulating factor (GMCSF) (63).
Despite the paucity, the data are promising and perioperative
treatment strategies, aimed at stimulating the cellular immune
system warrants further study. As outlined in the remainder of
this review, OV are an attractive agent to reverse perioperative
immune suppression.
WHY USE PERIOPERATIVE ONCOLYTIC VIRUSES FOR
IMMUNE STIMULATION? A MULTIPRONGED APPROACH
FOR A MULTIFACTORIAL PROBLEM
Oncolytic viruses are not considered a “traditional” immunother-
apy but their multiple mechanisms of action provide several
advantages over traditional cytokine immune stimulants in the
complex postoperative period. First, the immune stimulation pro-
vided by an OV is a more “physiological” immune stimulus,
engaging and maturing DC, which in turn activates NK and T
cells. The multitude of cytokines and chemokines, stimulate the
appropriate picomolar concentration, by a systemic virus infec-
tion would be impossible to replicate even with the most carefully
designed cytokine cocktail. Second, the OV will selectively replicate
in and kill residual cancer cells, providing a direct cytolytic effect
to remaining micrometastases, but also delivering the immune
response to the tumor selectively. Finally, there is strong rationale
to hypothesize that OV could infect and replicate better in the
postoperative state because of the surge of growth factors such as
VEGF, providing a therapeutic advantage for OV in postoperative
cancer patients.
PRECLINICAL EVIDENCE FOR NK CELL ACTIVATION
WITH PERIOPERATIVE ONCOLYTIC VIRUSES
Viruses, in general, are known to activate NK cells (64, 65) and
OV are no exception. One of the first reports to support the
anti-tumor activation of NK cells in response to OV therapy was
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reported by Diaz et al. in which depletion experiments were per-
formed to demonstrate that B16 melanoma tumor regression was
achieved in a CD8+ T and NK cell-dependent manner follow-
ing vesicular stomatitis virus (VSV) intratumoral (i.t.) injection
(66). Supporting these findings, oncolytic Reovirus treatment of
prostate cancer produced an anti-tumor CD8+ T cell response
along with prominent NK cell infiltration (67, 68). Miller et al.
also observed that i.t. therapy with oncolytic herpes simplex virus
(HSV) for B16 melanoma was abrogated in syngeneic models
lacking NK and T cell subsets (69). In mechanistic studies with
oncolytic new castle disease virus (NDV), Jarahian et al. demon-
strated enhanced NK cytotoxicity against human tumor cell lines
infected with NDV. Further, soluble receptor binding and blocking
assays suggest that NKp44 and NKp46 recognition of viral lig-
and hemagglutinin-neuraminidase on NDV infected tumor cells
mediated NK anti-tumor activity (70). We have demonstrated that
oncolytic ORF virus (ORFV) has a profound effect on NK cells
following i.v. delivery and that this NK cell activation is the main
mechanism by which ORFV exerts its anti-tumor effect (71). It
is very likely that stimulation of NK cells play an important role
in the therapeutic effect of many OV, not only by enhancing NK
cell-mediated killing of tumor target cells but also by triggering a
robust, T cell-mediated, anti-tumor immune response (72).
Given that surgery suppresses NK cell activity and OV activate
NK cells, we explored the ability of preoperative OV to pre-
vent postoperative NK cell suppression, and in turn prevent the
development of postoperative metastases. Using our established
murine model of surgical stress, we demonstrated that perioper-
ative administration of novel oncolytic ORF and vaccinia viruses
can reverse NK cell suppression following surgery and this corre-
lates with a reduction in the postoperative formation of metastases
(3). Similar effects were observed in 4T1-tumor bearing surgically
stressed mice treated with perioperative OV. When NK cells were
depleted, the effect was no longer present, suggesting that sup-
pression of tumor metastases in a surgical stress model is mainly
mediated through OV activation of NK cells and subsequent NK
cell-mediated tumor lysis (3).
We demonstrated a similar effect with the novel oncolytic
rhabdovirus, Maraba (MG1) and used this model to explore the
mechanism of NK cell activation further. MG1 is a double mutant
rhabdovirus with deletion in the G and M proteins (73). It is a clin-
ical candidate OV that is scheduled to begin a Phase I clinical trial
in 2014. MG1 infection in immune competent mice resulted in an
immediate (24 h) and intense activation of NK cells, as evidenced
by significantly increased NK cell cytotoxicity and cytokine secre-
tion. Moreover, preoperative i.v. administration of MG1 overcame
surgery-induced NK suppression and attenuated the development
of postoperative metastases in the B16lacZ model of implanted
lung metastases, as well as in the breast 4T1 model of spontaneous
lung metastases (74).
Mechanistically, we demonstrated that MG1 activates NK cells
through conventional DC (cDC) (Figure 1). Using an ex vivo
NK:DC co-culture system, we showed lack of NK infection,
activation, and cytotoxicity in the absence of cDC. Further, in
cDC ablated mice (CD11c-Diphtheria Toxin Receptor Transgenic
mice), NK cell cytotoxicity was significantly reduced following
MG1 administration (74). While we demonstrated that MG1 does
not directly infect or activate NK cells, this is not the case for other
OV. For instance, vaccinia virus has been shown to interact directly
with NK cells through Toll-like-receptor-(TLR)-2 (75).
As the interplay between OV and immune cells in the perioper-
ative period is critically important for the eradication of tumors,
we further explored these interactions in our preclinical models of
tumor and surgical stress. In both B16 melanoma and 4T1 breast
tumor models, we observed postoperative expansion of myeloid-
derived suppressor cells (MDSC) (3), which are known regulatory
cells that have been shown to expand following various patholo-
gies to suppress innate and adaptive immunity (76–80). The role of
MDSC on surgery-induced dysfunction of NK cells and antigen-
specific T cells and its potential interaction with OV is part of
ongoing research in our lab (Figure 1).
PRECLINICAL EVIDENCE OF TAA-SPECIFIC T CELL
ACTIVATION WITH PERIOPERATIVE ONCOLYTIC VACCINE
Oncolytic vaccines (OVax) are OV that express TAA that can
direct the host immune response toward the TAA while simulta-
neously performing viral oncolysis and creating an inflammatory
tumor microenvironment (81, 82). Dr. Brian Lichty has pioneered
this prime-boost OVax platform and demonstrated remarkable
efficacy in the B16 model (82–86). B16 cells express the TAA,
dopachrome tautomerase (DCT), which is a protein involved
in melanogenesis and is present in normal melanocytes and
melanoma. As previous studies have demonstrated, Ad-DCT is
able to prime a DCT specific T cell immune response and protect
mice from a B16 tumor challenge or tumor re-growth (87, 88), but
has limited efficacy in a therapeutic model of lung metastases (89).
Dr. Lichty’s group engineered MG1, to express DCT upon produc-
tive infection and used these two viruses in a prime-boost strategy
in tumor-bearing animals. They found that when Ad-DCT was
allowed to prime an immune response, followed 9 days later by an
MG1-hDCT boost, the results were remarkable, leading to a sig-
nificant reduction in lung metastases with durable cures in>20%
of mice, something not seen when MG1 expressing an irrelevant
transgene (MG1-GFP, green-fluorescent protein) was used. Strik-
ingly, ~27% of CD8+ T cells were directed against DCT. Selective
depletion of cytotoxic T lymphocytes (CTL) at the time of the
boost abrogates the therapeutic efficacy, underscoring their cen-
tral role. In the near and longer term, we will focus on using OVax,
such as MG1-DCT in preclinical mouse tumor models of surgical
stress to perioperative boost adaptive immune functions.
CLINICAL EXPERIENCE WITH PERIOPERATIVE OV IN CANCER
SURGERY PATIENTS
The compelling preclinical and clinical data with oncolytic vac-
cinia virus, in particular the evidence that it can stimulate a potent
anti-tumor immune response (90) led us to hypothesize that peri-
operative treatment with this OV could improve recurrence-free
survival following surgical resection. We designed a single center
Phase II clinical trial where patients with metastatic colorectal
tumors within the liver were treated with a single i.v. dose of
oncolytic vaccinia virus prior to surgical resection (91). This trial
explored the mechanisms of action of oncolytic vaccinia virus
through a series of correlative blood and tissue studies collected
from patients pre- and post-OV treatment and surgery. In this
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FIGURE 1 | Preoperative delivery of live/attenuated OV, viral vaccines,
and oncolytic vaccines enhances innate and adaptive immune cell
function to reduce postoperative metastatic disease. Preoperative
administration of the live or attenuated OV results in NK cell activation via
cDC; preoperative delivery of viral vaccines results in IFNα production (likely
through cDC), which results in NK cell activation, thereby preventing
surgery-induced dysfunction and removal of tumor cell emboli and
micrometastases in the postoperative period. Postoperative MDSC
expansion contributes to NK cell dysfunction and OV may reverse the
suppressive effects of MDSC. Preoperative oncolytic vaccines may activate
tumor antigen-specific CD8+ T cells and reduce tumor burden and increase
survival.
study, we confirmed that NK cell cytotoxicity improved in the set-
ting of pre-operative oncolytic vaccinia virus compared to baseline
control blood (3). Further, we detected genome copies of vaccinia
virus in the tumors of patients following resection (unpublished
data), which suggests that viral targeting of the tumor by i.v.
injection may elicit an immune response in the tumor. These
results demonstrated for the first time that oncolytic vaccinia virus
markedly increases NK activity in cancer surgery patients.
In the same patient population of CRC, systemic delivery of
oncolytic reovirus prior to planned surgical resection of liver
metastases was undertaken by researchers in the UK (92) In this
“window of opportunity” trial of 10 patients, Adair et al. was able
to recover live reovirus from the blood cells, but not from plasma
removed from these patients. In addition, reovirus protein was
identified preferentially in resected tumor tissue, but not in nor-
mal liver tissue. Their results suggest that immune cells in the
blood may protect virus from neutralizing antibodies, thus provid-
ing targeted delivery of OV to tumors. Importantly, preoperative
treatment with oncolytic reovirus was well tolerated, with the most
common side effects being flu-like symptoms and no reported
grade 3 or 4 toxicities in any patients (92). In a study of periopera-
tive oncolytic HSV delivery, virus was injected intratumorally pre-
and post-surgical resection into patients with recurrent glioblas-
toma multiforme (93). Evidence of immune cell infiltration and
viral replication in the resected tumors was reported by the
authors. Notably, no patients developed HSV related encephali-
tis or required antiviral treatment (93). In a series of clinical
trials using NDV-modified autologous tumor cell vaccine (NDV-
ATV) for treatment of colorectal, renal cell, and glioblastoma
cancer patients, researchers detected a significantly improved sur-
vival advantage compared to unvaccinated and historical controls.
However, NDV-ATV was mostly administered postoperatively and
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not preoperatively to prevent surgery-induced immunosuppres-
sion, which might further improve upon the survival advantage.
Similar to the above studies, NDV-ATV was well tolerated, with the
most common side effects being mild-fever/headache and no asso-
ciated autoimmunity (70, 94–99). These reports demonstrate the
feasibility of perioperative OV administration into cancer surgery
patients.
THE IMPORTANCE OF TIMING FOR OV ADMINISTRATION
IN THE PERIOPERATIVE PERIOD
While the postoperative period provides a window of opportunity
for cancer cells to metastasize and grow, it also provides a win-
dow of opportunity to intervene, by strengthening the immune
system and reducing recurrence of cancer following surgery in
cancer patients. In our preclinical perioperative vaccine studies,
we hypothesized that neoadjuvant delivery of vaccine immedi-
ately prior to surgery will allow for maximal NK cell stimulation
to counteract surgery-induced NK cell suppression (100, 101).
Indeed, we observed that influenza vaccine administered on the
same day, immediately prior to surgery, reduced metastases most
effectively. The results from NK cells isolated from cancer surgery
patients also confirm that the timing of influenza administration is
critical for its effect. In four out of four cancer surgery patients, NK
cells isolated prior to surgical resection demonstrated enhanced
cytotoxicity and IFNγ secretion following ex vivo pulsing with
influenza vaccine, while in only one of these patients was simi-
lar activation demonstrated in NK cells isolated 1 day following
surgery, suggesting that surgery-induced NK cell dysfunction can
be prevented but not reversed by influenza. In humans receiving
a flu shot as part of a vaccination campaign, NK cell activation
peaked at 1–2 days following immunization (101). Based on this,
it appears that a cancer vaccination strategy is probably best deliv-
ered the day before cancer surgery, in order to allow sufficient time
to maximally activate NK cells prior to surgical stress.
Equally important for a replicating virus is the growth advan-
tage that the postoperative state may provide, increasing oncolysis,
viral replication, and spreading. Surgical stress results in a surge
of VEGF with resulting angiogenesis to facilitate wound healing
(21). Kottke et al. (102, 103) have previously demonstrated that
a VEGF surge improved viral replication, viral cell lysis, and an
innate immune mediated attack, in particular by NK cells, by
allowing tumor-associated endothelial cells to transiently support
viral replication during the VEGF surge. The sequential combi-
nation of oncolytic vaccinia virus and the small molecule B-raf
and VEGF inhibitor, sorafenib, has also demonstrated efficacy in
preclinical models and a few patients (104), further supporting the
concept that OV and VEGF may act synergistically if the timing of
viral administration is considered.
BARRIERS TO PERIOPERATIVE OV THERAPY
AND STRATEGIES TO OVERCOME THEM
While these data are exciting, the perioperative use of OV is in
preclinical and early stages of clinical investigation. In the design
of our preoperative OV trial, we were confronted with multiple
concerns associated with the use of a live virus immediately prior
to surgery in cancer patients. In particular, concerns were raised
about the potential for an overwhelming postoperative systemic
inflammatory response, the risk of spread to members of the oper-
ating room team, and risk of meningitis with epidural analgesia.
These safety concerns present real barriers to the development of
perioperative OV. In their recent publication, Adair et al. demon-
strated the feasibility and safety of perioperative live reovirus
infusion prior to surgery in CRC patients. However, OV infusion
was administered 6–28 days prior to surgery and not immedi-
ately before surgery. Further, three patients received fewer than
their planned five doses of reovirus. In one patient, this was due
to a decline in white blood cell count, while the remaining two
patients opted to not receive their last doses of OV prior to surgery
because of their own concerns that flu-like symptoms might inter-
fere with the planned surgery, highlighting a strongly held belief
that remains a theoretic barrier to immediate preoperative delivery
of a replicating virus (92).
Given these very real concerns surrounding live perioperative
delivery of OV, we subsequently focused on generating non-
replicating MG1 viruses to characterize their ability to activate NK
cells and attenuate metastases in a model of experimental (B16)
and spontaneous (4T1) metastases following surgical stress. To
accomplish this, we constructed a replication incompetent MG1 –
MG1-Gless-eGFP, that is only capable of one infectious life cycle,
thus offering a safe in vivo profile. Next, we compared these varia-
tions of MG1: (1) live MG1-productive infection and replication;
(2) a G-less version (MG1-Gless) – capable of a single-replication
cycle of virus; (3) MG1 exposed to ultraviolet (UV) for 2 min to
2 h – replication incompetent confirmed by plaque assay. MG1,
MG1-Gless, and MG1-UV2 min exhibited significantly higher NK
cell function compared to PBS control, and they effectively atten-
uated in vivo B16lacZ lung metastases to near identical levels
at high viral doses (1× 108 PFU). However, at all lower doses
studied (1× 105–7 PFU), live MG1 demonstrated better efficacy
than attenuated MG1. Furthermore, we characterized this panel
of MG1 viruses in terms of virus morphological structure and
cell associated interaction via Electron Microscopy, qRT-PCR, and
western blot and found that MG1-UV2 min remains an intact virus
particle (virus proteins, genetic materials) with cell-associated
interactions, corresponding to the highest NK cell activation and
least lung metastases, among MG1-UV viruses. Importantly, we
demonstrated that preoperative i.v. administration of equivalent
high doses (1× 108 PFU) of live and attenuated MG1 (MG1-Gless
or MG1-UV2 min) overcame surgery-induced NK cell suppres-
sion and reduced the development of postoperative metastases
in the B16lacZ implanted lung metastases, as well as in the breast
4T1 model of spontaneous lung metastases. Taken together, these
results suggest that the intact viral particle and cellular recogni-
tion, along with viral proteins and genomic RNA are essential for
NK cell-mediated anti-tumor responses. Non-replicating forms of
MG1, including MG1-UV2 min, are novel cancer therapies that can
be safely used in the immediate preoperative period to prevent the
formation of metastatic disease (74).
Parallel to our perioperative attenuated OV studies, we
assessed a wide range of potential agents to provide periop-
erative non-specific immunostimulation including TLR ligands
and inactivated vaccines against infectious disease. Firstly, we
assessed a panel of routinely used immunizations, including
vaccines against influenza, meningitis, measles/mumps/rubella,
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diphtheria/tetanus/pertussis/polio, pneumonia, and influenza for
their ability to activate (CD69 expression) and enhance NK cell
function (cytotoxicity and IFNγ secretion). When directly com-
pared, influenza was the most potent NK cell activator among
the prophylactic vaccines, although, not unexpectedly, inoculating
mice with live replicating viruses (such as vaccinia virus) induced
higher levels of NK cell cytotoxicity. Using our mouse models of
experimental (B16 melanoma) and spontaneous (4T1) metastases
and surgical stress, we subsequently demonstrated that preoper-
ative delivery of a single dose of influenza resulted in a dramatic
reduction in lung metastases (101). In order to confirm that NK
cells play a mediating role in preventing postoperative metastases
following influenza treatment, we pharmacologically depleted NK
cells and observed a complete abrogation of the therapeutic effect
of influenza vaccination. Furthermore, we discovered that IFNα
had the most dramatic increase following influenza vaccination
after assessing a panel of serum cytokines following influenza
administration. We also observed that low-dose preoperative IFNα
was able to rescue surgery-induced NK cell dysfunction and metas-
tases to the same degree as influenza vaccination. The central role
for IFNα was underscored by demonstrating that influenza vac-
cination was not able to increase postoperative NK cell activity
or attenuate postoperative metastases in IFNα receptor-deficient
mice. In PBMC isolated from human donors, Type I IFN block-
ing antibody prevented influenza from activating NK cells (101).
While our study did not explore the role of DC in the produc-
tion of IFNα following influenza vaccination, it is very likely that
they represent the primary source, resulting in secondary NK cell
stimulation (see Figure 1).
CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS
Surgical resection is the mainstay of therapy for patients with
localized solid malignancies. Even with complete resection, many
patients develop a metastatic recurrence and ultimately die of their
disease. The immediate postoperative period provides an ideal
environment for the formation of cancer metastases. Despite this,
it remains a therapeutic window that is largely ignored. There are
currently no standard perioperative anti-cancer therapies aimed
at preventing postoperative metastases. We have demonstrated
in preclinical models that perioperative OV therapy can activate
both the innate and adaptive immune responses and attenuate
metastatic disease. Early clinical trials confirm the feasibility of
this strategy but these therapies must be rigorously character-
ized for safety and efficacy and then translated into thoughtfully
designed clinical trials. This research supports the concept that
neoadjuvant (preoperative) OV treatments can reverse postop-
erative immune dysfunction, while directly infecting and killing
tumor cells and creating a favorable immune microenvironment.
This treatment strategy has the potential to impact countless can-
cer patients who undergo surgical resection of their solid tumor
every year.
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